swine flu stockpiling

Check out this report:
http://www.dailymarkets.com/stocks/2009/04/27/swine-flu-impact-on-anti-viral-sales-use-of-tamiflu-and-relenza-will-come-from-stockpiles/
Quote: Gilead Sciences receives a 20% royalty on worldwide Tamiflu sales
Peter Cook should be sacked for his most idiotic cooked settlement. He refused the approximately $100million GSK offer in 2006, went on to burn another $10m of legal fees, and then settled for $20 million. Thinking that shareholders will not be wiser to the GSK offer, the idiot told shareholders it was a wonderful outcome, blamed the financial losses on Peter Molloy (the previous CEO) and asked shareholders to reward him with 430,600 options. Despite shareholders voting down the resolution, the idiot collected his options and announced it on 19 Dec 08 hoping shareholders were too busy celebrating Xmas to notice.

Unlike the idiot Peter Cook, Gilead settled their law suit against Roche with an increased 20% royalty. They went on to maximise Tamiflu sales to the Avian Flu stockpiling market at the expense of Relenza and poor BTA shareholders.

It is interesting to note that the above report was written prior to the emergence of Tamiflu resistance Swine Flu H1N1 virus.
Quote: “Tamiflu sales in 2007 were $1.7 billion, of which $1.3 billion was pandemic stocking and $0.4 million was seasonal use.”

With the continuing spread of Swine flu will the pandemic stockpiling be equal to the Avian flu stockpiling in 2007? Given the swineflu virus resistance to Tamiflu, will Relenza capture the majority of the stockpiling?
During the Avian flu stockpiling Relenza formed only 5% of the sales and yet GSK was forced to increase production to between 30 to 45 million course per annum.
Months ago, Relenza formed 1/3 of the Australian stockpile and for the first time outsold Tamiflu in Japan. IMHO the coming Relenza sales report will show demand far exceed GSK production capacity. There is every reason to expect Relenza demand to be in the hundres of million courses.

With the continuing spread of swine flu and growing viral resistance to Tamiflu, GSK planned 60 million courses p.a is seriously inadequate. What is the idiot Peter Cook doing? The only news we hear from him is talking down the share price and blaming shareholders and traders and today we see the idiots lining their pocket with 383,260 free shares.

Why did Peter Cook failed to report the extension to the Japanese Patent to the ASX?
Why did Peter Cook failed to report recent Reelnza sales to the ASX?
Why did Peter talked down the share price?
The idiot stand to gain more options from a lower June share price??